

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad - 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



31st July, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sir,

Sub: Outcome of Board Meeting and Submission of Audited Financial Results for the year ended on 31st March, 2020, Date of Annual General Meeting, Book Closure & E-voting.

We refer to our letter dated 20th July, 2020 informing the date of Meeting of the Board of Directors of the Company.

(A) Please note that the Board of Directors in their meeting held today have approved the Audited Financial Results for the financial year 2019-20 ended on 31st March, 2020.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith:

1. Statement of Audited Financial Results for the year ended on 31st March, 2020.
2. Auditors' Report on the Audited Financial Results

(B) Further, the Board of Directors of the Company in their meeting held today have decided to:

1. Convene the 32nd Annual General Meeting of the Members of the Company at 11.00 a.m. on Wednesday, the 30th September, 2020 through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) in compliance with the applicable provisions of the Companies Act, 2013 read with MCA General Circular no. 14/2020, dated 8th April, 2020, MCA General Circular no. 17/2020, dated 13th April, 2020, MCA General Circular No. 20/2020 dated 5th May, 2020 and MCA General Circular no. 22/2020, dated 15th June, 2020.
2. The Register of members and Share Transfer Books of the Company will remain closed from Thursday, the 24th September, 2020 to Wednesday, the 30th September, 2020 (both days inclusive) for the purpose of the above referred 32nd Annual General Meeting.

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad - 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



KAMRON

3. The Company has provided its Shareholders the facility to cast their vote by Electronic means i.e. Remote e-voting and e-voting system during the AGM on all the resolution set forth in the notice of 32nd Annual General Meeting.

1	Date & Time of commencement of Remote e-voting	at 9.00 a.m. on Sunday, 27 th September, 2020
2	Date & Time of end of Remote e-voting	at 5:00 p.m. on Tuesday, the 29 th September, 2020
3	Cut-off date for determining rights of entitlement of Remote e-voting	Wednesday, 23 rd September, 2020
4	E-voting system during the AGM shall not be allowed beyond	15 minutes after the conclusion of AGM

This is in due compliance of the relevant Regulations of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED

Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN: 00461198)



KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER/ FINANCIAL YEAR ENDED ON 31ST MARCH, 2020

(Rs. In lakh)

Particulars		Quarter ended on			Year ended on	
(Refer Notes Below)		31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	137.09	178.92	104.84	659.12	559.42
2	Other income	0.63	1.04	13.29	2.34	24.89
3	Total Income (1+2)	137.72	179.96	118.13	661.46	584.31
4	Expenses					
	a. Cost of Materials consumed	0	53.69	21.83	54.43	95.76
	b. Purchases of stock-in-trade	46.00	41.37	36.65	270.14	150.56
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(26.23)	180.97	(199.58)	162.94	(103.87)
	d. Employee benefits expense	75.39	44.14	30.30	194.67	151.62
	e. Finance costs	1.78	0.23	1.65	2.02	7.27
	f. Depreciation & amortisation expense	(4.45)	8.90	18.41	42.26	73.44
	g. Other expenses	98.82	72.94	25.32	310.55	206.49
	Total Expenses	191.31	402.24	(65.42)	1037.01	581.27
5	Profit / (Loss) before exceptional items and tax (3-4)	(53.59)	(222.28)	183.55	(375.55)	3.04
6	Exceptional items	0.77	18.16	-	18.93	-
7	Profit / (Loss) before tax (5-6)	(52.82)	(204.12)	183.55	(356.62)	3.04
8	Tax expense:					
	Current tax	-	-	-	-	-
	Deferred tax	-	-	-	-	-
	Earlier year			0.28	-	0.28
9	Profit/ (Loss) for the period from continuing operations (7-8)	(52.82)	(204.12)	183.27	(356.62)	2.76
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit / (Loss) for the period (9+12)	(52.82)	(204.12)	183.27	(356.62)	2.76

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



Particulars		Quarter ended on			Year ended on	
		31-03-2020 (Audited)	31-12-2019 (Unaudited)	31-03-2019 (Audited)	31-03-2020 (Unaudited)	31-03-2019 (Audited)
14	Other Comprehensive Income					
	<i>Items that will not be reclassified subsequently to profit or loss</i>		-	-		-
	Mention Item.....					
	Mention Item.....					
	Income tax relating to items that will not be reclassified to profit or loss		-	-		-
	<i>Items that will be reclassified subsequently to profit or loss</i>		-	-		-
	Mention Item.....					
	Mention Item.....					
	Income tax relating to items that will be reclassified to profit or loss		-	-		-
	Other Comprehensive Income, net of tax		-	-		-
15	Total Comprehensive Income for the period (13+14)	(52.82)	(204.12)	183.27	(356.62)	2.76
16	Paid-up equity shares capital (Face Value per share Rs. 10 each)	585.00	585.00	585.00	585.00	585.00
17	Reserves excluding Revaluation Reserves					112.84
18	Earnings Per Share of Rs.10 each (for continuing operations)					
	- Basic	(0.90)	(0.35)	3.13	(6.10)	0.05
	- Diluted	(0.90)	(0.35)	3.13	(6.10)	0.05
19	Earnings Per Share of Rs.10 each (for discontinued operations)					
	- Basic		-	-		-
	- Diluted		-	-		-
20	Earnings Per Share of Rs.10 each (for discontinued & continuing operations)					
	- Basic	(0.90)	(0.35)	3.13	(6.10)	0.05
	- Diluted	(0.90)	(0.35)	3.13	(6.10)	0.05



FOR, KAMRON LABORATORIES LTD.,

Kamron
MANAGING DIRECTOR

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



STATEMENT OF ASSET & LIABILITIES:

(Rs. in Lakh)

Sr. No.	Particulars	As at 31-03-2020	As at 31-03-2019
	ASSETS		
1	Non-Current Assets		
	Property, plant and equipment	11.69	1137.61
	Capital work-in-progress		-
	Investment property		-
	Goodwill		-
	Other intangible Assets	466.47	60.92
	Intangible Assets under development		-
	Investments accounted for using equity method		-
	Biological Assets other than bearer plants		-
	Non-Current Financial Assets:		
	(i) Investments, Non-Current		-
	(ii) Trade receivables, Non-Current		-
	(iii) Loans, Non-Current	3.42	3.57
	Deferred tax Assets (net)		-
	Other Non-Current Assets		-
	Total Non-Current Assets	481.58	1202.10
2	Current Assets		
	Inventories	109.17	323.82
	Current financial asset:		
	(i) Current investments		-
	(ii) Trade receivables, Current	143.08	208.16
	(iii) Cash and cash equivalents	5.23	16.96
	(iv) Bank balance other than above		-
	(v) Loans, Current	8.94	6.72
	(vi) Other Current financial Assets		-
	Current tax Assets (net)		-
	Other Current Assets	10.38	426.81
	Total Current Assets	276.8	982.47
	TOTAL ASSETS	758.38	2184.57



FOR, KAMRON LABORATORIES LTD.

Kamrun Khan
MANAGING DIRECTOR

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



KAMRON

Sr. No.	Particulars	As at 31-03-2020	As at 31-03-2019
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	585.00	585.00
	Other Equity	(238.35)	118.26
	Total Equity	346.65	703.26
2	Liabilities		
	Non-Current Liabilities		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	-	-
	(ii) Trade payables, Non-Current		
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-
	(iii) Other Non-Current financial Liabilities	-	-
	Provisions, Non-Current	30.45	24.68
	Deferred tax Liabilities (net)	4.59	4.59
	Deferred government grants, non current	-	-
	Other Non-Current Liabilities	-	-
	Total Non-Current Liabilities	35.04	29.27
	Current Liabilities		
	Current financial Liabilities:		
	(i) Borrowings, Current	285.45	535.15
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	55.43	169.52
	(iii) Other Current financial Liabilities	-	-
	Other Current Liabilities	26.23	746.78
	Provisions, Current	9.58	0.59
	Current tax Liabilities (Net)	-	-
	Deferred government grants, current	-	-
	Total Current Liabilities	376.69	1452.04
	Total Liabilities	411.73	1481.31
	TOTAL EQUITY AND LIABILITIES	758.38	2184.57


KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
GIN : L24231GJ1988PLC010956



Notes:

1	The figures for quarter ended on 31 st March, 2020 and 31 st March, 2019 are the balancing figures between the audited figures in respect of the full financial year ended on 31 st March, 2020 & 31 st March, 2019 and the year to date figures upto the third quarter of the financial year.
2	The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.
3	The Company does not have any subsidiary / associate.
4	Figures, wherever required, are regrouped / rearranged. There are no material adjustments made in the results of the earlier periods.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 31 st July, 2020
6	The Statutory Auditors have carried out an audit of the above results for the financial year ended 31 st March, 2020 and have issued an unmodified opinion on the same.
7	<p>The World Health Organisation (WHO) declared the novel Coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020. Consequent to this, Government of India had declared lockdown on March 23, 2020 and therefore, the Company suspended its business operations . COVID-19 has impacted the normal business operations of the Company by way of interruption in production, supply chain disruption, closure of production facilities etc. during the lock-down period. However, business operations resumed from (01-05-2020) after obtaining necessary permissions from the appropriate government authorities. We have also taken necessary precautions to ensure the health, safety and wellbeing of all our employees as well as put in place SOPs and guidelines as per state government directives to prevent the spread of Covid-19. The Company has made detailed assessment of its liquidity position for FY 2021 and the recoverability and carrying value of its assets comprising property, plant and equipment, intangible assets, right of use assets, investments, inventory, and trade receivables. Based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The situation is changing rapidly giving rise to inherent uncertainty around the extent and timing of the potential future impact of the COVID-19 which may be different from that estimated as at the date of approval of these standalone and consolidated financial results. The Company will continue to closely monitor any material changes arising of future economic conditions and impact on its business.)</p>

Date: 31th July, 2020 Place : Ahmedabad	For KAMRON LABORATORIES LIMITED  KAMLESH J. LASKARI MANAGING DIRECTOR (DIN: 00461198)
--	--



Cash Flow Statement for the year ended 31st March 2020

(Amount in Rs.)

	Year ended 31 st March, 2020	Year ended 31 st March, 2019
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit after tax <i>(Loss) before Tax</i>	(3,56,60,996)	2,76,363
Adjustments for,		
Depreciation/ amortization	42,26,575	73,44,158
Profit on sale/ write off of fixed assets(net)	(45,06,780)	(50,000)
Depreciation on Sales of assets		-
Provision for doubtful debts/ advances written back		-
Adjustments to the carrying amount of investments-reversal of reduction in The carrying amount of non-current investments		-
Interest expense	202242	7,27,545
Interest income	(19888)	(139)
Net loss/ (gain) on foreign currency translations		-
Share of loss in the partnership firm where the Company is a partner		-
Dividend on long-term investments(non-trade)		-
Bad debts written off		-
Excess provision of earlier years written back		-
Provision for doubtful debts/ advances		-
Operating profit before working capital changes Sub Total A	(35758847)	82,97,927
(Increase)/ decrease in trade receivables	(6508525)	19,68,998
(Increase)/ decrease in inventories	2,14,64,574	(94,76,003)
(Increase)/ decrease in loans and advances	(1244165)	25,85,743
Increase/ (decrease) in trade and other payables	(10,69,58,820)	(1,28,31,052)
(Increase) / Decrease Pre Expenses		-
(Increase) / Decrease Deferred revenue exp		-
Sub Total B	(80229886)	(1,77,52,314)
Cash generated from operations (A-B)	(115988733)	(94,54,387)
Direct taxes and fringe benefit tax paid		
Net cash generated from operating activities-I	(11,59,88,733)	(94,54,387)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	(523429)	(28,51,732)
Capital Work in Progress		-
Share of loss in the partnership firm where the Company is a partner		-
Amounts paid for acquiring debts From a bank on assignment basis		-
Purchase of investments		-
Sale of Investment		-
Profit on Sales of assets	(113308000)	50,000
Dividend income		-
Interest income	(19888)	139
Net cash (used in) investing activities -II Sub Total C	(112804459)	(28,01,593)



FOR, KAMRON LABORATORIES LTD.

Kamrun / Lankan
MANAGING DIRECTOR

Cash Flow Statement(Contd.)

	Year ended 31 st March, 2020	Year ended 31 st March, 2019
CASH FLOW FROM OPERATING AND INVESTING ACTIVITIES III (I +II)		(1,22,55,980)
C.CASH FLOW FROM FINANCING ACTIVITIES		
Calls in arrears received during the year (including securities premium)		-
Buy back of equity shares		-
Repayment of debenture		-
Repayments of other borrowings		(23,62,94
Proceeds/ (repayments) of other borrowings(net)		2,02,751
Gratuity Provision		-
Income tax Provision		-
Interest expense	(202242)	(7,27,545
Net cash (used in)/ from financing activities Sub Total D	(202242)	(28,87,74
Net increase/(decrease)in cash and cash equivalents (III+D)	(3786516)	(1,51,43,721)
Cash and cash equivalents at the beginning of the year	1695597	1,68,39,3
Cash and cash equivalents at the end of the year	522641	16,95,597

(Amount in Rs.)



FOR, KAMRON LABORATORIES LTD.
Kamlesh J. Lankar
 MANAGING DIRECTOR

**INDEPENDENT AUDITORS' REPORT****TO THE BOARD OF DIRECTORS OF KAMRON LABORATORIES LTD****Report on the audit of the Standalone Annual Financial Results****Opinion**

We have audited the accompanying standalone annual financial results of KAMRON LABORATORIES LTD for the year ended 31st March, 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone annual financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the year ended 31st March, 2020

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the





preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.





We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matter

The standalone annual financial results include the results for the quarter ended 31st March, 2020 and the corresponding quarter ended in the previous year being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year which were subject to limited review by us.



For RANGWALA & CO
Chartered Accountants
(Firm's Registration No.115833W)


Z.E. RANGWALA

Partner

(Membership Number: 031268)

UDIN: 20031268AAAAAZ9367

Place: Ahmedabad

Date: 31st July 2020

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad - 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010986



31st July, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sir,

Sub: Declaration regarding Audit report with unmodified opinion with respect to Annual Audited Financial Results for the Financial Year ended 31st March, 2020

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and SEBI Circular No.CIR/CFD/CMD/56/2016 dated 27th May, 2016, it is hereby declared and confirmed that Auditors' Report obtained from M/s. Rangwala & Co., Chartered Accountants on Annual Audited Financial Results of the Company for the financial year ended 31st March, 2020 has an unmodified opinion.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For KAMRON LABORATORIES LIMITED

Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN: 00461198)

